Latest News

• share
• favorite_border

A bladder cancer drug discovered and developed at The University of Kansas Cancer Center is set to become its first cancer drug to go from bench to bedside.

• share
• favorite_border

The University of Kansas Cancer Center and Children’s Mercy Hospital have announced four first-of-their-kind endowed chair appointments that will help eliminate childhood diseases around the world.

• share
• favorite_border

Researchers at The University of Kansas Cancer Center have found that high doses of drugs commonly used to fight high cholesterol can destroy a rogue protein produced by a damaged gene that is associated with nearly half of all human cancers

• share
• favorite_border

Statement supports shorter dosing schedule, urges action to increase national vaccination rates

• share
• favorite_border

Researchers are studying a new injectable chemo that has shown to be successful in canines.

• share
• favorite_border

Jennifer Klemp, PhD, MPH, director of cancer survivorship and an associate professor at The University of Kansas Cancer Center, is interviewed by Oncology Nursing News. In this interview, Klemp offers insights on some of the critical issues that clinicians face, among them: how to deliver optimal survivorship care, what ingredients go into the plan, how to measure progress, and how is this care reimbursed.

• share
• favorite_border

Currently, excess body weight contributes to as many as 1 in 5 cancer-related deaths. Obesity is associated with increased risk of at least eight types of cancer. The American Society of Clinical Oncology has identified obesity as a health risk that is “quickly overtaking tobacco as the leading preventable cause of cancer.”

• share
• favorite_border

Allen M. Chen, M.D., has been appointed the new Joe and Jean Brandmeyer Chair of the Department of Radiation Oncology at the University of Kansas School of Medicine. He will join the faculty on October 1, 2016.

• share
• favorite_border

Dr. Carol Fabian honored for her work changing the odds for women with breast cancer and those at increased risk for the disease.

• share
• favorite_border

Yoshiaki Azuma, Ph.D., is analyzing the role of enzyme Topo II and how its functions may show how cancer mutations are born.

• share
• favorite_border

KU Cancer Center researchers Liang Xu, Ph.D., and Kristi Neufeld, Ph.D. are studying gossypol, a natural compound currently going through early phase clinical trials for prostate cancer.

• share
• favorite_border

NIH grant will help create Kansas PKD Research and Translation Core Center

• share
• favorite_border

Trial trains patients' re-engineered cells to chase down the cancer and destroy it

• share
• favorite_border

Trials trains patients' re-engineered cells to chase down the cancer and destroy it

• share
• favorite_border

A team of researchers led by KU Cancer Center Cancer Prevention & Survivorship Program member, Animesh Dhar, Ph.D., found that crocetinic acid, a purified compound from crocetin, showed the inhibition of growth in human pancreatic cancer cells grown either in a dish or as tumors under the skin of mice.

• share
• favorite_border

Clinical trial improves outcomes with safer, more effective therapy

• share
• favorite_border

Priyanka Sharma, M.D., is looking at what she’s calling “BRCAness” or deficiency in DNA damage repair machinery in triple-negative breast cancer as a potential prognostic and predictive marker.

• share
• favorite_border

A new study of a biomarker that can identify DCIS patients who are not at risk for subsequent invasion could save many lives and keep women from having to go through medical and surgical therapy.

• share
• favorite_border

Understanding how these organisms trigger the transformation of normal cells to cancerous ones is the focus of a new National Cancer Institute grant awarded to Shahid Umar, Ph.D., of The University of Kansas Cancer Center.

• share
• favorite_border

KU Cancer Center researcher is finding out why ovarian cancer is resistant to certain types of chemo to eventually identify a different drug target.